Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Megan Stasi"'
Autor:
Jennifer L. Winkelmann, Jason A. Konner, David M. Hyman, Jerrold B. Teitcher, Nora Katabi, Alan L. Ho, Alexia Iasonos, Alexandra Snyder, Kelsey R. Monson, Mario E. Lacouture, John F. Gerecitano, Megan Stasi, Martin H. Voss, Richard D. Carvajal, Matthew G. Fury, Philip A. Bialer, David R. Spriggs
Publikováno v:
Cancer Chemotherapy and Pharmacology. 75:747-755
PURPOSE: Phosphatidylinositol-3-kinase I (PI3K) inhibition sensitizes a wide range of cancer cell lines to platinum/taxane-based chemotherapy. This phase I study combines buparlisib, a pan-class 1A PI3K inhibitor, with two schedules of carboplatin an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b31d39d3a9945f84f496c1f5aa440b97
https://doi.org/10.1007/s00280-015-2693-z
https://doi.org/10.1007/s00280-015-2693-z
Autor:
Kelsey R. Monson, J. Winkelman, A.E. Snyder Charen, Martin H. Voss, Richard D. Carvajal, Megan Stasi, John F. Gerecitano, Nora Katabi, David M. Hyman, Mrinal M. Gounder, Matthew G. Fury
Publikováno v:
Annals of Oncology. 25:iv156
Aim: Carboplatin and paclitaxel are mainstays of treatment for metastatic solid tumors, and the PI3K/mTOR pathway is one of the most commonly dysregulated in cancers. The combination of PI3K inhibition and platinum-based chemotherapy may enhance anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c240e5335e79c683acb23d0efd935168
https://doi.org/10.1093/annonc/mdu331.29
https://doi.org/10.1093/annonc/mdu331.29
Autor:
John F. Gerecitano, Gary K Schwartz, Richard Carvajal, Matthew Fury, Jason Konner, David M. Hyman, Mrinal Gounder, Devika Gajria, Jerrold Teitcher, Zhigang Zhang, Craig H. Moskowitz, Jan H Beumer, Alice Chen, Richard F Little, Fallon France, Juho Whang, Jennifer Winkelman, Megan Stasi, Corey Russell, Naomi Cazeau, Katherine Kargus, Andrew D. Zelenetz
Publikováno v:
Blood. 122:4366-4366
Background PARP is overexpressed in many malignancies, and can protect tumor cells from genetic damage. The PARP inhibitor ABT-888 (A) enhances the cytotoxicity of several alkylating agents. Since bendamustine (B) is an alkylator with promising clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5bfae962d93447846092dd4db2ece4e
https://doi.org/10.1182/blood.v122.21.4366.4366
https://doi.org/10.1182/blood.v122.21.4366.4366